Gabapentin (GBP) is a drug which is frequently used in diabetic neuropathy. 
Introduction

Diabetic neuropathy is a common complication of diabetes mellitus (DM) and occurs in approximately 50% of diabetic patients over time (1). Gabapentin (GBP), an anticonvulsant, has been shown to be efficacious in the treatment of painful diabetic neuropathy (PDN) (2). The most frequent side effects (>10%) of GBP include somnolence, dizziness, ataxia, and fatigue. Other side effects are nystagmus, headache, tremor, diplopia and nausea, each occurring in less than 10% of patients (3). In recent years, two reports have suggested that GBP may be associated with myopathy
. In this report, we describe a case of rhabdomyolysis and myoglobinuria complicated by acute renal failure following the use of GBP in a patient with PDN. 
Case Report
T a b l e 1 . L a b o r a t o r y Re s u l t s o f t h e P a t i e n t
Discussion
In this report we presented a case of rhabdomyolysis complicated by acute renal failure in a patient receiving GBP for PDN. Gabapentin was thought to be the causal agent based on the following factors: the temporal relationship between the onset of symptoms, which occurred one week after the introduction of the drug; the clinical and biochemical resolution, which occurred after discontinuation of the drug; the absence of an alternative explanation for the rhabdomyolysis, as there was no trauma, signs of infection, thyroid dysfunction, or additional new medications. In addition, the Naranjo probability scale (6) indicated a probable (8 points) relationship between rhabdomyolysis and GBP therapy.
Rhabdomyolysis is a condition characterized by muscle necrosis resulting in the release of muscle cell contents into the systemic circulation. The classic triad of signs includes muscle injury, pigmented urine due to myoglobinuria, and renal dysfunction. The severity of illness ranges from asymptomatic elevations in serum muscle enzymes to lifethreatening cases associated with extreme enzyme elevations, electrolyte imbalances, and acute renal failure (7, 8) .
Rhabdomyolysis has many etiologies. Among the most common are trauma, intense exercise, infection, drugs, and toxins. Exposure to toxic agents, including alcohol and medications, accounts for up to 80% of rhabdomyolysis cases in adults (7, 8) . Several drugs, including statins, fibrates, neuroleptics, colchicine and proton pump inhibitors may cause rhabdomyolysis (7) (8) (9) (10) . In the literature, to the best of our knowledge, there are two case reports with respect to GBP use and myopathy (4, 5 (11, 12) . In literature, published cases of GBP related adverse events including rhabdomyolysis occurred mostly in the setting of either acute or chronic renal dysfunction (4, 5, (13) (14) (15) (5, 16, 17) .
In conclusion, GBP may be associated with rhabdomyolysis and it should be considered in the differential diagnosis of drug induced rhabdomyolysis. Appropriate dosing adjustments and close laboratory follow-up should be made in patients receiving GBP in case of renal insufficiency.
